Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

Phase 2

Completed

Conditions: Graves' Disease

Interventions: Drug: CFZ533

First Posted Date: 2016-03-18

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT02713256

Locations: 🇩🇪
Novartis Investigative Site, Mainz, Germany

Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Phase 2

Completed

Conditions: Non-cystic Fibrosis Bronchiectasis

Interventions: Drug: TIP
Drug: TIP and placebo
Drug: Placebo

First Posted Date: 2016-03-18

Last Posted Date: 2020-08-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 107

Registration Number: NCT02712983

Locations: 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom

To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.

Phase 2

Completed

Conditions: Primary Bile Acid Diarrhea

Interventions: Drug: LJN452
Drug: Placebo to LJN452

First Posted Date: 2016-03-18

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT02713243

Locations: 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Phase 1

Terminated

Conditions: Ovarian Neoplasms
Non-Small-Cell Lung Carcinoma
Melanoma
Other Solid Tumors

Interventions: Drug: LTT462

First Posted Date: 2016-03-17

Last Posted Date: 2019-09-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT02711345

Locations: 🇨🇭
Novartis Investigative Site, Bellinzona, Switzerland

A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Trametinib
Drug: Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)

First Posted Date: 2016-03-11

Last Posted Date: 2022-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT02705963

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
Karmanos Cancer Institute Karmanos Cancer Institute, Detroit, Michigan, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors for Phase Ib
Pancreatic Cancer for Phase II
Colorectal Cancer for Phase II

Interventions: Drug: ribociclib
Drug: Trametinib

First Posted Date: 2016-03-09

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT02703571

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States

and more 4 locations

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

Phase 4

Completed

Conditions: Mild to Moderate Alzheimer's Disease

Interventions: Drug: Rivastigmine Patch

First Posted Date: 2016-03-09

Last Posted Date: 2019-09-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT02703636

Locations: 🇯🇵
Novartis Investigative Site, Okayama, Japan

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

Phase 3

Completed

Conditions: Cushing's Disease

Interventions: Drug: osilodrostat
Drug: osilodrostat Placebo

First Posted Date: 2016-03-03

Last Posted Date: 2021-11-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 73

Registration Number: NCT02697734

Locations: 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey
🇺🇸
Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States
🇺🇸
University of Colorado Endocrinology Clinical Trials Unit, Aurora, Colorado, United States

and more 4 locations

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

Phase 3

Completed

Conditions: Non-radiographic Spondyloarthritis

Interventions: Drug: Secukinumab
Drug: Placebo

First Posted Date: 2016-03-02

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 555

Registration Number: NCT02696031

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

A Study of CLR325 in Chronic Stable Heart Failure Patients.

Phase 2

Completed

Conditions: Chronic Stable Heart Failure

Interventions: Drug: CLR325
Other: Placebo

First Posted Date: 2016-03-02

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT02696967

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy